chevron_leftBack
As of 10 June 2026, Daewoong Pharmaceutical Co., Ltd. has a market cap of $1.13B USD, ranking #10034 globally and #272 in South Korea.
It ranks #884 in the Healthcare sector, and #334 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$1.13BUSD
1.72T KRW
Enterprise Value
$1.64BUSD
2.51T KRW
Revenue (TTM)
$1.03BUSD
1.57T KRW
EBITDA (TTM)
$161.47MUSD
246.58B KRW
Net Income (TTM)
$128.33MUSD
195.86B KRW
EBITDA Margin
16%
Profit Margin
12%
PE Ratio
8.8
Forward PE
10.4
PS Ratio
1.1
PB Ratio
1.5
EV/EBITDA
8.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
1,644
Founded
1945
Website
daewoong.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.9% | -0.1% | -10% | -12% | 6.3% | 15% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
069620
(주)대웅제약
ISIN: KR7069620003
Shares Out.:
Shares Outstanding:
11.506M1
Shares Float:
4.449M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
148,300 KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Daewoong Pharmaceutical Co., Ltd.
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
KRX: 0126Z0
|
$9.11B
708%
13.91T KRW
|
-
|
|
KRX: 000250
|
$6.75B
499%
10.3T KRW
|
1958.1
|
|
KRX: 326030
|
$5.22B
363%
7.97T KRW
|
29.9
|
|
KRX: 298380
|
$4.95B
338%
7.55T KRW
|
-
|
|
KRX: 000100
|
$4.53B
302%
6.92T KRW
|
35.9
|
|
KRX: 141080
|
$4.43B
293%
6.76T KRW
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
67K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
48K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
32K%
|
97.4
|
|
SIX: RO
|
$321.17B
28K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$287.57B
25K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.35B
24K%
218.9B CHF
|
20.5
|
chevron_leftBack